Avita Medical Inc Stock Price, News & Analysis

AVITA Medical (NASDAQ: RCEL) reported Q3 2025 results for the quarter ended September 30, 2025. Commercial revenue was $17.1M, down 13% year-over-year. Operating expenses fell 24% to $23.0M, and net loss improved to $13.2M, or $0.46 per share, from $16.2M a year earlier. Cash, cash equivalents, and marketable securities totaled $23.3M at quarter end after a $13.8M private placement.

Key developments: RECELL GO received CE Mark under the EU MDR enabling launches in Germany, Italy, and the U.K.; real-world data showed a 36% reduction in hospital length-of-stay and approximately $42,000 per-patient cost savings versus split-thickness grafts; full-year 2025 revenue guidance was lowered to $70–$74M. The company amended its credit agreement, adding $500,000 to loan principal and resetting a revenue covenant to $70M for Q4 2025.

AVITA Medical (NASDAQ: RCEL) presented two studies at the 2025 Southern Region Burn Conference reinforcing the RECELL System as a standard of care in acute wound treatment. A global systematic review of 99 studies (>8,000 patients, 13 countries) found RECELL reduces donor site size (up to 97.55%), achieves rapid wound closure comparable or superior to STSG, and shows favorable pain, aesthetic, and health-economic outcomes. A U.S. registry analysis (ABA Burn Care Quality Platform; >8,500 RECELL patients) reported a 36% shorter hospital stay (5.6 days; p<0.0001), 83% discharged home vs 70% for STSG, and estimated cost savings of >$42,000 per patient.

AVITA Medical (NASDAQ: RCEL) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a conference call and webcast the same day at 1:30 p.m. Pacific Time (Friday, November 7, 2025 at 8:30 a.m. Australian Eastern Daylight Time) to discuss results and recent business highlights.

The live webcast will be available in the Events & Presentations section of AVITA Medical's investor website at ir.avitamedical.com. Telephone participants must register in advance to receive dial-in details and a personal PIN; a replay will be posted on the investor site shortly after the live event.

AVITA Medical (NASDAQ: RCEL) announced that Australia’s Medical Services Advisory Committee (MSAC) recommended amendments to the Medicare Benefits Schedule to include autologous skin cell suspension (ASCS) prepared with RECELL for severe acute burn wounds in adults and children.

MSAC concluded RECELL is as safe and effective as traditional autologous skin grafting and noted benefits including donor site sparing, reduced need for additional grafting, shorter hospital stays, less pain, and minimized scarring. Recommended uses include adults with ≥20% TBSA, pediatrics with ≥10% TBSA, and whole-of-face closure.

AVITA Medical (NASDAQ: RCEL) announced an immediate CEO transition: Board Chairman Cary Vance is named Interim CEO and will remain Chairman, while former CEO Jim Corbett is leaving the company. Board member Jan Stern Reed was appointed Lead Independent Director and the Board will engage a search firm to find a permanent CEO, considering internal and external candidates including Mr. Vance.

The Company expects preliminary Q3 2025 revenue of approximately $17 million. AVITA secured a waiver from OrbiMed for the Q3 2025 trailing 12-month net revenue covenant and is negotiating revised future covenants. An earnings call is scheduled for November 6, 2025.

AVITA Medical (NASDAQ: RCEL) announced that hospitals will now be eligible for New Technology Add-on Payment (NTAP) reimbursement from CMS when using RECELL to treat non-burn trauma and surgical full-thickness wounds. Starting October 1, 2025, hospitals can receive up to $4,875 in additional reimbursement per case through September 30, 2026.

The NTAP designation was granted under CMS's alternative pathway for FDA Breakthrough Devices. A clinical trial published in the Journal of Trauma and Acute Care Surgery demonstrated that RECELL achieved comparable wound closure while requiring 27% less donor skin compared to standard skin grafting. The technology prepares Spray-On Skin™ cells from a small sample of the patient's healthy skin.

AVITA Medical (NASDAQ: RCEL) has received CE Mark approval under the EU Medical Device Regulation for RECELL GO, enabling commercialization across Europe and other markets that recognize the CE Mark. RECELL GO is a point-of-care device that prepares Spray-On Skin™ Cells from a patient's own skin sample to promote healing in burns and traumatic or surgical wounds.

Recent data presented at the 2025 European Burns Association Congress showed that adults with deep partial-thickness burns treated with RECELL experienced a 36% reduction in hospital stays compared to traditional grafting. The company plans to begin commercialization in select European countries, including Germany, Italy, and the United Kingdom.

AVITA Medical (NASDAQ: RCEL) announced compelling real-world data demonstrating significant benefits of its RECELL® System in burn treatment. The analysis from the U.S. national burn registry showed that RECELL reduces hospital length of stay by 36% compared to traditional skin grafts in adults with deep second-degree burns.

The study of 741 adults revealed RECELL-treated patients experienced an average 5.6-day reduction in hospital stay, potentially saving over $42,000 per patient in costs. The system enables hospitals to treat 13 more patients per bed annually. RECELL requires 97.5% less skin compared to traditional grafts while improving donor site healing, pain, and scarring.

AVITA Medical (NASDAQ: RCEL) has announced its participation in three major investor conferences this September. The company's management will engage in the following events:

• Cantor Global Healthcare Conference on September 4, featuring a fireside chat with CFO David O'Toole
• Morgan Stanley Global Healthcare Conference on September 8, with CEO Jim Corbett
• Lake Street Capital Markets Best Ideas Growth Conference on September 11, with CFO David O'Toole

The Morgan Stanley fireside chat will be available via webcast for 90 days on AVITA Medical's investor relations website.